anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
HIV-infected patients treated with combination antiretroviral (ARV) therapy increasingly demonstrate metabolic abnormalities, including dyslipidemia, insulin resistance and body composition abnormalities that may predispose them to cardiovascular disease (CVD). Initial studies suggest increased carotid intima-media thickness (IMT) and endothelial dysfunction in this population. Increased carotid IMT over time has been demonstrated in HIV-infected patients compared to control subjects. However, traditional risk factors, such as dyslipidemia, diabetes mellitus and body composition changes alone do not fully predict increased cardiovascular disease in HIV-infected patients. One possible explanation is increased inflammation, related directly to effects of ARV therapy or indirectly from changes in fat distribution. In preliminary studies, our group has shown that changes in fat distribution were highly predictive of TNF and IL-6, as well as adiponectin, and that specific inflammatory cytokines were related in cross-sectional studies to increased IMT. In the proposed study we will investigate using detailed methodologies the relationship between adipocytokine concentrations and subclinical atherosclerosis in both cross-sectional and longitudinal studies. We will determine in HIV-infected patients on ARVs for greater than 6 months, progression rates of IMT and whether progression rates are predicted by increased inflammatory indices, controlling for traditional risk factors, and body composition changes. We will test the hypothesis that inflammation, more than traditional risk factors and ARV use, mediates subclinical atherosclerotic disease in HIV-infected patients.
Participants used a device produced by Maxstar Corp. (Gimpo, South Korea), which specializes in pneumatic compression appliance manufacture. The IPC device (UAM-9306NB) was cleared by National Institute of Medical Device Safety Information (NIDS) of Korea (approval number: 18-4745). This device consists of a six-chamber pneumatic sleeve and a gradient-sequential pneumatic pump.
PROBLEM TO BE SOLVED: To provide an aerosol type ointment hardly scattering blowout products, scarcely causing the flow of a stuck liquid on application, and having a high adhesion rate to applied sites. SOLUTION: This aerosol type ointment composition comprises a stock solution containing a mineral oil and a thickener, and a propellant. The stock solution has a viscosity of 1,000-200,000 cps at 20 deg.C. The thickener is selected from paraffin waxes, fats, fatty oils, vegetable extraction waxes, animal extraction waxes, higher alcohols and hydrocarbon-based polymers. The mineral oil is preferably a hydrocarbon-based compound which is liquid at in a range of 0 deg.C to 60 deg.C. The propellant is selected from a liquefied petroleum gas, dimethyl ether and compressed gases. The stock solution and the propellant are preferably used in a weight ratio of 30:70 to 70:30.
Assessing changes in lifestyle, dietary habits, eating behaviors, and stress during the pandemic and their impact on weight is crucial for developing effective interventions. This study investigated weight variations among Brazilians and associated habit changes over nine months during the COVID-19 pandemic. An online questionnaire was applied (T0/T1, T2). Weight variation classifications were determined from T0 to T1 and evaluated longitudinally for changes in lifestyle, dietary habits, food consumption, eating behavior, and perceived stress using generalized estimating equations (p < 0.05). Out of 453 participants, 23.6% lost weight, 18.1% maintained their weight, 26.0% gained up to 2.4 kg, and 32.2% gained ≥ 2.5 kg. Weight loss was associated with decreased food consumption and increased stress at T2. The group that gained up to 2.4 kg reported reduced food intake, snacking, meal preparation, and candy consumption but increased stress at T2. Those gaining ≥ 2.5 kg initially increased food consumption, snacking, meal preparation, hamburgers/canned products, sugary drinks, instant meals/snacks, candies, and fast food consumption at T1, all of which were reduced at T2, along with a decrease in uncontrolled and emotional eating. Although the pandemic initially affected daily habits differently based on weight changes, participants-especially those who gained more weight-tended to revert to pre-pandemic habits.
The invention relates to the technical field of biological products for livestock, and particularly discloses an 8 a-type avian adenovirus strain, an inactivated vaccine, a preparation method and application thereof. The strain belongs to group I E type 8a, is named as DK02 strain, and is preserved in China Center for Type Culture Collection (CCTCC) NO: V202170. Experiments show that the DK02 strain provided by the invention is suitable for suspending LMH cells (chicken liver cancer cells), and has the advantages of high toxicity, strong pathogenicity and good immunogenicity. The invention also provides an application of the DK02 strain in preparing vaccines for preventing inclusion body hepatitis. The invention provides an inactivated vaccine of avian I group adenovirus serum 8a type, which is used for preventing inclusion body hepatitis. After the chicken is immunized, the chicken 'inclusion body hepatitis' caused by the 8a adenovirus of the poultry I group in recent years can be well prevented, the toxicity attack protection rate is high, the safety is high, the antibody is produced quickly, and the efficacy is stable.
Histopathologic data have revealed that up to 70% of ovarian cancers may actually arise from the fallopian tube. Thus, opportunistic bilateral salpingectomy is now promoted for women at the time of hysterectomy for a benign disease. In turn, the potential surgical risks and ovarian cancer prevention of this emerging practice have generated multiple studies, some of which reported microscopic fimbriae were left behind adherent to the ovary. Although it is thought that there is no direct connection between the ovary and its adjacent fallopian tube, the investigators often find remnants of the fimbria adherent to the ovary at the time of surgery. If this tubo-ovarian interface is not separate, then practices such as salpingectomy and radical fimbriectomy may be incomplete, and the effectiveness of this technique as a prophylactic strategy may need reconsideration. In this study, the investigators aim to assess the presence of residual fimbrial/tubal tissue on ovarian surfaces following salpingectomy and to discuss the efficacy of this procedure on the reduction of epithelial ovarian cancer. Patients who undergo salpingo-oophorectomy +/- hysterectomy (laparoscopic or laparotomy) for benign indications, early cervical cancer or low-risk endometrial cancer will be included. Patients with other pelvic malignancies, previous bilateral salpingectomy or bilateral oophorectomy and excessive adhesions will be excluded. Salpingectomy with or without hysterectomy, as indicated, will be performed initially. This will be followed by bilateral oophorectomy as a second step within the same procedure. The ovaries and tubes removed will be sent in separately labelled containers: right tube, left tube, right ovary and left ovary. Histological assessment will be performed by gynecological pathologists. The fallopian tubes will be sectioned serially and ovaries will also be serially sectioned and examined for presence of any remnant tubal tissue.
Rapid-onset and short-acting agents should be preferred in induction, and full induction doses should be applied since they do not receive premedication and increased volume of distribution. Rapid serial induction and intubation should be performed in pregnancies greater than 20 weeks due to the risk of aspiration. Magnesium potentiates and prolongs the effect of nondepolarizing neuromuscular blocking agents. It is recommended that the TOF value be between 0 and 2 for adequate muscle relaxation in cesarean section anesthesia. In anesthesia induction; thiopental 3-6mg/kg, rocuronium 1mg/kg, and fentanyl 1mcg/kg and dormicum 2mg will administered after the baby birth. Sevoflurane 2-3% and 50% oxygen + 50% air are used for maintenance. If TOF is 0, sugammadex 4mg/kg will be administered to reverse the effect of the muscle relaxant.A blood sample will be taken to measure simultaneous calcium and magnesium values. Patients with a TOF ≥0.9 (gold standard for extubation) or patients will be clinically evaluated and the decision to extubate will be made.
About 6 months after infection, HIV viral load reaches a temporarily stable level known as virus set point. Virus set point is different for each patient and can be a predictor for disease progression. Preliminary studies indicate that early, short-term antiretroviral therapy (ART) given to people newly infected with HIV may lead to lower virus set points and preserved CD4 counts. However, the length of short-term treatment needed to balance the possible adverse effects of ART with the achievement of lower virus set point is not yet known. By lowering the virus set point and maintaining CD4 counts, the need for long-term ART may be postponed. The purpose of this study is to determine the safety and efficacy of a short course of ART on producing a lower virus set point in adults recently infected with HIV.

This study will last at least 28 weeks. Participants will be randomly assigned to one of two arms. Arm A will receive ART for 12 weeks as emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) daily and lopinavir/ritonavir (LPV/RTV) in tablet form twice daily. After 12 weeks, treatment will be interrupted unless the CD4 count is measured to be less than 350 cells/mm\^3 on two consecutive occasions during treatment interruption. If that occurs therapy will be resumed. Participants in Arm B will receive no treatment until cluster of differentiation 4 (CD4) counts drop below 350 cells/mm\^3, indicating ART is needed. Study visits will occur at study entry, at Weeks 2 and 4, and every 4 weeks thereafter. At each study visit, a physical exam, blood collection, and completion of an adherence questionnaire will occur. Participants are encouraged to enroll in a related substudy that will evaluate HIV viral load in genital secretions.
PURPOSE:To obtain a treating and preventive agent for neuropathy caused by denaturation of neurocytes, containing a carboxylic acid or salt thereof as an active ingredient and capable of improving productivity of cells producing nervous growth factors. CONSTITUTION:The aimed substance obtained by using a carboxylic acid expressed by the formula or salt thereof alone or in a mixture with a normally used carrier. The above-mentioned substance is preferably used as intravenous injection or drops. In this case, 0.1-20wt.% carboxylic acid is blended as an active ingredient. The dose thereof is 0.6-60mg per day. Gallic acid and pyrogallol-4-carboxylic acid are exemplified as the carboxylic acid. For example, the substance is useful for treating and preventing Alzheimer's dementia, Huntington's chorea, etc.
Peripheral arterial disease (PAD) is a common disorder, affecting 12% of adults older than 50 years of age. Approximately one third of these patients experience intermittent claudication, defined as pain in the thigh or calf muscles during walking and that resolves with rest. Lower extremity pain is often severe enough to significantly limit ambulation, forcing many patients to seek medical care. Current treatments include two FDA-approved medications, supervised walking programs, arterial angioplasty and/or stent placement, and open arterial bypass surgery. The problem is that noninvasive treatments are oftentimes ineffective, while invasive treatments are effective but expensive.

A non-invasive lower extremity treatment that has shown success in treating lymphedema and venous insufficiency will be studied during this protocol to assess its effects on claudication symptoms. Half of the participants in this prospective, single-center randomized controlled trial will be treated with a pneumatic compression device in a home treatment program, while half will receive standard medical therapy. If effective, potential benefits are high, providing relief of personal disability and avoidance of costly surgical intervention.
Patients randomized to the CSCI will attend a 120-minutes survivorship clinic in which each participant will be assessed by members a multidisciplinary team comprising a registered nurse, a dietitian, an exercise physiologist and a psychologist/counsellor. During the visit, participants will receive a personalized (1) treatment summary, (2) assessment and recommendation on managing physical and psychological symptoms, (3) assessment and recommendation on dietary advice, (4) assessment and recommendation on physical activity, and (5) advice on managing potential psychosocial issues. While this is a multidisciplinary clinic, the nurse will be the core facilitator who will give a summary of health assessment report including personalized healthy lifestyle advice and action plan to each participant at the end of the visit.
States are identified in a time ordered sequence of data that have a temporal component. Data that includes a plurality of snapshots is received. Each snapshot of the plurality of snapshots includes a plurality of sensor measurements captured from distinct sensors at a common time point. The plurality of snapshots are time ordered. Root mean square error (RMSE) values are computed between successive pairs of the plurality of snapshots in time order. A peak is identified in the computed RMSE values. A valley is identified in the computed RMSE values. A stable state is determined as occurring from the identified peak to the identified valley. The determined stable state is output.
The invention discloses a vascular endothelial growth factor receptor partial polypeptide and application thereof. The amino acid sequence of the vascular endothelial growth factor receptor partial polypeptide is Sequence 1 in the sequence table. The polypeptide can be coupled with a carrier protein to form a compound protein. The carrier protein is a keyhole limpet hemocyanin or bovine serum albumin. The mixture of the compound protein and an immunological adjuvant can be used as an immunogen. The immunogen immunized animal acquires high-titer immune serum. The ELISA inspection indicates that the titer is higher than 1:60000; and the immunobiotting test proves that the immune serum has strong specificity when being combined with a chicken vascular endothelial growth factor receptor, and can be used for detecting the expression of the chicken vascular endothelial growth factor receptor on the cellular level.
Patients aged 50 or above diagnosed with myeloid neoplasms (MNs) are typically not candidates for germline testing. However, approximately 8% carry pathogenic germline variants. Allogeneic haematopoietic stem cell transplantation (alloHSCT) remains an option for those aged over 50; neglecting germline testing could mask the risk for relative donor cell-derived MN. We propose a germline-augmented somatic panel (GASP), combining MN predisposition genes with a myeloid somatic panel for timely germline variant identification when initial testing is not indicated. Out of our 133 whole-exome-sequenced MN cases aged over 50 years, 9% had pathogenic/likely variants. GASP detected 92%, compared to 50% with somatic-only panel. Our study highlights the relevance of germline screening in MN, particularly for alloHSCT candidates without established germline-testing recommendations.
Treatment of cells with ionizing radiation is associated with the production of arachidonic acid. Inhibition of phospholipase A2 abolishes radiation-mediated arachidonate production, protein kinase C induction and tumor necrosis factor gene expression. The addition of inhibitors of lipoxygenase, such as ketoconazole, prior to irradiation reduces the expression of of tumor necrosis factor while maintaining the expression of other radiation inducible genes, such as Egr-1 and c-jun. In contrast, indomethacin, an inhibitor of cyclooxygenase, enhanced the expression of tumor necrosis factor as well as other radiation inducible genes. The results show that lipoxygenase inhibitors are useful in the treatment of radiation-induced mucositis, dermatitis, pneumonitis, proctitis, and esophagitis. which may be due to the production of cytokines such as TNF.
This group will receive supplemental videos on taVNS and TMS. Participants will be in this group for approximately 7 hours.
GSK2126458 will be dosed continuously (every day) for the duration a 28 day cycle. The 28 day cycles will continue until the subjects withdraw from the study.
PROBLEM TO BE SOLVED: To obtain a hair grower excellent in depilation-preventive effect and hair growing effect, containing a combination of specific plant extract(s) with an amine oxide. SOLUTION: This hair grower contains 0.005-20wt.%, on a dry basis, of an extract from Arnica momtana L. and 0.0001-20wt.% of an amine oxide of the formula (R<1> is a 2-24C alkyl; R<2> is methyl or hydroxyethyl; A is monoxyethylene; (n) is 0-5) (e.g. N,N-dihydroxymethyl-2-dodecylamine oxide). The extract is obtained from the flower of the corresponding plant. The extractant to be used is an organic solvent. This hair grower is effective for treating/ preventing depilation, being administered percutaneously, for example, through direct coating or spraying on the skin; its daily dose is 0.01-100mg/kg for adult in one to four portions per day.
Nonwoven webs having reduced levels of lint and slough are disclosed. In accordance with the present invention, the nonwoven webs are treated on at least one surface with a small amount of a polymeric component. The polymeric component may be present, for instance, in the form of meltblown fibers. The meltblown fibers are made from a polymer that is compatible with the nonwoven web. By adding relatively small amounts of meltblown fibers to at least one side of the nonwoven material, lint and slough levels have been found to be significantly reduced. The nonwoven web may be any web containing pulp fibers, such as a tissue web or a coform web.
Relaxation is a low-cost treatment for managing pain with little or no side effects. The proposed study will use a novel biofeedback treatment to try and enhance the capacity of relaxation to engage pain inhibitory circuits. Specifically, a biofeedback system (Biofeedback Training for Conditioned Pain Regulation, BT-CPR) will be used to monitor the participant's level of sympathetic arousal and will use this to control the intensity of painful stimulations delivered to the participant during biofeedback training. Thus, when the participant successfully relaxes (and reduces their arousal), the intensity is lowered and produces pain relief. Efficacy of the treatment will be tested in a small, randomized controlled trial in which individuals with a verified diagnosis of chronic musculoskeletal pain will receive 10 treatment sessions, or 10 sessions of a control condition (traditional biofeedback, to control for the effects of relaxation on pain). The aim will be to assess whether the treatment results in improvements in clinical pain outcomes (e.g., pain intensity, quality of life, pain interference) and psychosocial variables (e.g., coping, self-efficacy, mood).
Patients undergo SOC SBRT over 3 fractions on days 1, 3, and 5, followed by M5A-ICK SC on days 8, 9, and 10 once daily for a single cycle on study. Patients undergo CT or PET/CT as well as blood sample collection throughout the trial. Patients may undergo magnetic resonance imaging or bone scan as clinically indicated on the trial. Additionally, patients may optionally undergo tissue biopsy during screening and on study.
Early bactericidal activity (EBA), which measures decline in serial sputum colony forming unit (CFU) counts over the first 2-14 days of treatment, has been used extensively as a means of initially evaluating the potency of individual or combinations of antituberculous agents. This approach is endorsed by the Global Alliance for TB Drug Development and the US FDA. However, EBA seems to correlate poorly with the relative ability of an agent to prevent relapse and produce a durable cure (often referred to as sterilizing activity ). The reasons for this discrepancy may have to do with a limitation of sputum measurements to capture populations that persist beyond airway surfaces in discrete lesions such as granulomas, nodules, or cavities. The elimination of these persistent populations depend on the pharmacodynamic properties of a regimen and may be better captured by biologic and functional markers that can reflect dynamic treatment effects within these relevant host environments.

Recent studies of the response to TB chemotherapy have identified promising new biomarkers of sterilization in 2 areas. First, immunologic changes appear to have potential in small subject cohorts to predict sterilizing cure within 1 month after commencing treatment. Second, 18F-FDG PET/CT has been used in tuberculosis as a qualitative means of assessing drug response in small case series at multiple time points, starting as early as 1 month. PET activity reflects uptake and phosphorylation of FDG by neutrophils and macrophages, and CT provides structural information on disease pathology. Hence, PET/CT data may offer additional insights into lesion-specific sterilizing activity. This study will add 18F-FDG PET/CT scans and immunological assays at 0, 2, and (in the HRZE arm) 4 weeks to standard EBA methodology using regimens containing isoniazid (INH \[H\]), rifampin (RIF \[R\]), pyrazinamide (PZA \[Z\]), moxifloxacin (MXF \[M\]), and ethambutol (EMB \[E\]). We hypothesize that drug regimens associated with higher sterilizing activity (e.g., containing rifampin or pyrazinamide) will show distinctive early cytokine and chemokine patterns and discrete, quantifiable changes on PET/CT in certain lesion types during the 2-week period, compared to drug regimens with poor sterilizing activity (e.g., containing isoniazid or moxifloxacin). Demonstration of such an association would provide rationale for including radiologic and immunologic analysis, alongside conventional EBA, in early phase clinical studies of novel drugs, and would also provide important new insights into the biology of human and bacterial responses to TB drugs.